ClinicalTrials.gov
ClinicalTrials.gov Menu

Integrated Microfluidic System for Oral Diagnostics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00277745
Recruitment Status : Completed
First Posted : January 16, 2006
Last Update Posted : December 14, 2015
Sponsor:
Collaborators:
Sandia National Laboratories
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
Information provided by (Responsible Party):
William Giannobile, University of Michigan

January 12, 2006
January 16, 2006
December 14, 2015
June 2005
February 2007   (Final data collection date for primary outcome measure)
Proof of principle study to determine ability of device to predict disease activity in patients at high and low risk for disease. [ Time Frame: 2 years ]
Proof of principle study to determine ability of device to predict disease activity in patients at high and low risk for disease.
Complete list of historical versions of study NCT00277745 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Integrated Microfluidic System for Oral Diagnostics
Integrated Microfluidic System for Oral Diagnostics
This study is being conducted to test the ability and accuracy of a new instrument in the diagnosis of periodontitis (gum disease) by using fluids from the mouth. The diagnosis instrument will test two types of fluids, gingival crevicular fluid (GCF) and saliva. GCF is the fluid that accumulates between your teeth and gum tissue. The fluids will be collected in three ways: 1. Direct GCF sampling 2. GCF rinse sampling and 3. Whole saliva. A total of 100 adult patients will participate in this study. These subjects will be of two patient populations: 1) diseased population, with active gum disease; and 2) a low-risk disease population, with no active gum disease. Patients will be seen 6 times over the course of the study over a period of approximately 12 months. At each visit the patient will undergo oral fluid collection, as previously described, and thorough examinations of the mouth, including the taking of measurements for study purposes. Patients will also have radiographs taken at baseline, month 6, and end of study visits.
The ultimate goal of this investigation is to validate the ability of the prototype platform (miniaturized microfluidic device that can rapidly (within 15 minutes) measure small volumes of oral fluids (on the order of nanoliters of fluid) and identify biomarkers of disease such as mediators of inflammation (interleukins -1 and -6; C-reactive protein (CRP), and a marker of bone resorption (ICTP). This analysis will aid in the diagnosis of active periodontal (gum) disease as well as diseases involved in systemic inflammation (e.g., cardiovascular disease) or systemic bone loss (osteoporosis). This project will have two specific goals: 1. To validate the ability of the diagnostic to measure the designated mediators from oral fluids; and 2. Determine the ability of the multiplexed format of mediator analysis to predict disease activity (future bone loss) in patients at high and low risk for disease. This proposed feasibility study will then aid in providing the impetus for sample size and other design requirements for larger, more expanded human clinical trial testing and subsequent technology transfer.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Saliva, serum, dental plaque and gingival crevicular fluid
Non-Probability Sample
100 Adult subjects comprised of two populations: 1) disease susceptible (n=50) and 2) low-risk disease (n=50)
  • Healthy
  • Periodontitis
Device: miniaturized microfluidic system
Subjects will provide appropriate periodontal treatment as needed.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Same as current
June 2007
February 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must possess at least 20 teeth and not have received periodontal treatment or antibiotic-related therapy for medical or dental reasons 3 months prior to study inclusion.
  • Low-risk inclusion: < 3 mm of attachment loss, no pockets > 4 mm, possess no radiographic bone loss, and < 20 sites with bleeding on probing (BOP). Low-risk cohort will be comprised of at least > 50% of the subjects above age 35 in order to exam low risk patients in other age strata (so as to decrease potential bias towards a younger population in the low risk cohort).
  • Disease-susceptible inclusion: Exhibit at least 4 sites with evidence of radiographic bone loss, mean attachment loss > 3 mm, pocket depths (PD) > 4 mm and BOP.

Exclusion Criteria:

  • Long-term use of medications known to affect periodontal status such as anti-inflammatory drugs (NSAIDS and aspirins)
  • History of metabolic bone diseases such as rheumatoid arthritis or post-menopausal osteoporosis.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00277745
H03-00003522
U01DE014961-01 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
William Giannobile, University of Michigan
University of Michigan
  • Sandia National Laboratories
  • National Institutes of Health (NIH)
  • National Institute of Dental and Craniofacial Research (NIDCR)
Principal Investigator: William V Giannobile, DDS, DMedSc Director of MCOHR
University of Michigan
December 2015